Sutro Biopharma, Inc. (NASDAQ:STRO) appears in 61 institutional 13F filings for the quarter ending December 2025.
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| BVF INC/IL | 31 Mar, 2026 | 1,251,788 | 1,251,788 | 0.00% | $31,182,039.00 |
| Affinity Asset Advisors, LLC | 31 Mar, 2026 | 1,069,519 | 321,137 | 42.91% | $26,641,718.00 |
| Samsara BioCapital, LLC | 31 Mar, 2026 | 1,062,872 | 858,369 | 419.73% | $26,476,142.00 |
| Kynam Capital Management, LP | 31 Mar, 2026 | 872,558 | 392,968 | 81.94% | $21,735,420.00 |
| ORBIMED ADVISORS LLC | 31 Mar, 2026 | 801,144 | 801,144 | 0.00% | $19,956,497.00 |
| VANGUARD CAPITAL MANAGEMENT LLC | 31 Mar, 2026 | 720,442 | 720,442 | 0.00% | $17,946,210.00 |
| RA CAPITAL MANAGEMENT, L.P. | 31 Mar, 2026 | 715,307 | 715,307 | 0.00% | $17,818,297.00 |
| PERCEPTIVE ADVISORS LLC | 31 Mar, 2026 | 715,307 | 715,307 | 0.00% | $17,818,297.00 |
| EVENTIDE ASSET MANAGEMENT, LLC | 31 Mar, 2026 | 715,307 | 715,307 | 0.00% | $17,818,297.00 |
| Point72 Asset Management, L.P. | 31 Mar, 2026 | 692,111 | 513,023 | 286.46% | $17,240,485.00 |
| ADAR1 Capital Management, LLC | 31 Mar, 2026 | 524,441 | 390,287 | 290.92% | $13,063,825.00 |
| Velan Capital Investment Management LP | 31 Mar, 2026 | 512,160 | 200,160 | 64.15% | $12,757,906.00 |
| BALYASNY ASSET MANAGEMENT L.P. | 31 Mar, 2026 | 465,792 | 235,743 | 102.48% | $11,602,879.00 |
| Woodline Partners LP | 31 Mar, 2026 | 457,441 | 457,441 | 0.00% | $11,394,855.00 |
| UBS Group AG | 31 Mar, 2026 | 392,871 | 385,001 | 4,892.01% | $9,786,416.00 |
| ACADIAN ASSET MANAGEMENT LLC | 31 Mar, 2026 | 335,813 | -2,140 | -0.63% | $8,363.00 |
| Merck & Co., Inc. | 31 Mar, 2026 | 272,351 | 0 | 0.00% | $6,784,263.00 |
| ACUTA CAPITAL PARTNERS, LLC | 31 Mar, 2026 | 269,425 | 201,974 | 299.44% | $6,711,377.00 |
| BlackRock, Inc. | 31 Mar, 2026 | 232,684 | 115,247 | 98.14% | $5,796,159.00 |
| KVP Capital Advisors, LP | 31 Mar, 2026 | 226,575 | 226,575 | 0.00% | $5,643,983.00 |